高尿酸合并高血压患者URAT1 6092(T/C)基因多态性对氯沙坦降尿酸疗效的影响

摘要/Abstract

摘要： 目的: 探讨尿酸盐阴离子转运体(Urate Transporter 1,URAT1)SNP6092(T/C)基因多态性对高尿酸血症合并原发性高血压患者服用氯沙坦降尿酸疗效的影响。方法: 应用PCR-RFLP方法对101名高尿酸血症合并原发性高血压患者和117名健康对照者进行基因分型,并且所有患者均每天口服氯沙坦药物 100 mg,连服2周。测定用药前后的血压、血尿酸(Ur)、尿素氮(BUN)、肌酐(Cr)、胆固醇(CHOL), 高密度脂蛋白胆固醇(HDL-c), 低密度脂蛋白胆固醇(LDL-c)和甘油三酯(TG)。结果: 服用氯沙坦后,突变基因型患者(TC/CC)的Ur和Cr的降低水平均明显低于TT基因型患者(P<0.05),并且TC和CC型患者的Ur降低幅度(1.34%±2.12%,-0.2%±3.8%)也明显低于TT基因型患者(22.58%±14.46%)(P<0.05)。结论: URAT1基因6092T/C遗传变异影响氯沙坦的降尿酸疗效,并且可能是氯沙坦降尿酸潜在的遗传靶点。

关键词: 氯沙坦, URAT1, 高尿酸, 高血压, 基因多态性

Abstract: AIM: To investigate the effect of URAT1 6092(T/C) polymorphism on uricosuric action of losartan in Chinese hyperuricemia patients with hypertension.METHODS: A total of 101 patients and 117 healthy controls were enrolled to identify 6092T/C genotypes by polymerase chain reaction restriction fragment length polymorphism assay.All patients received orally losartan as a single-dose therapy (100 mg/d p.o.) for 2 weeks. The blood pressure,serum creatinine(Cr), blood urea nitrogen (BUN),serum uric acid(Ur), total cholesterol(CHOL), high-density lipoprotein cholesterol (HDL-c), low density lipoprotein cholesterol (LDL-c) and triglyceride(TG) were determined before and after losartan treatment.RESULTS: After treatment,patients with the T6092C polymorphism TC/CC genotype showed significant lower levels. Compared with patients with the TT genotype,the decreased value and percentage of Ur, Cr was low ,moreover, patients with CT/CC genotype also showed significant lower levels of decreased percentage of Ur (1.34%±2.12%,-0.2%±3.8%) compared with patients with the TT genotype (22.58%±14.46%)(P<0.05).CONCLUSION: These results suggest that URAT1 6092(T/C) polymorphism can influence the uricosuric action of losartan and it is potential genetic markers for the optimization of losartan uricosuric action.

Key words: losartan, URAT1, hyperuricemia, hypertension, polymorphism

中图分类号:

R968

黄旭慧, 孙红, 蔡加琴, 具明玉. 高尿酸合并高血压患者URAT1 6092(T/C)基因多态性对氯沙坦降尿酸疗效的影响[J]. 中国临床药理学与治疗学, 2015, 20(4): 435-440.

HUANG Xu-hui, SUN Hong, CAI Jia-qin, JU Ming-yu. URAT1 allele 6092(T/C) polymorphism influence uricosuric action of losartan in hyperuricemia patients with hypertension[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(4): 435-440.

参考文献

[1] Hamada T, Hisatome I, Kinugasa Y, et al. Effect of the angiotensin II receptor antagonist losartan on uric acid and oxypurine metabolism in healthy subjects[J]. Intern Med,2002,41(10):793-797.
[2] Rayner BL, Trinder YA, Baines D, et al. Effect of losartan versus candesartan on uric acid, renal function, and fibrinogen in patients with hypertension and hyperuricemia associated with diuretics[J].Am J Hypertens, 2006,19(2):208-213.
[3] Puig JG, Mateos F, Buno A, et al. Effect of eprosartan and losartan on uric acid metabolism in patients with essential hypertension[J].J Hypertens,1999,17(7):1033-1039.
[4] Schmitt F, Natov S, Martinez F, et al. Renal effects of angiotensin I-receptor blockade and angiotensin convertase inhibition in man[J]. Clin Sci,1996, 90(3): 205-213.
[5] Nishida Y, TakahashiY, Susa N, et al. Comparative effect of angiotensin II type I receptor blockers on serum uric acid in hypertensive patients with type 2 diabetes mellitus: a retrospective observational study[J].Cardiovasc diabetol,2013,12(1):159.doi: 10.1186/1475-2840-12-159.
[6] Enomoto A, Endou H. Roles of organic anion transporters (OATs) and a urate transporter (URAT1) in the pathophysiology of human disease[J]. Clin Exp nephrol, 2005,9(3):195-205.
[7] Iwanaga T, Sato M, Maeda T, et al. Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter[J]. J Pharmacol Exp Ther, 2007, 320(1):211-217.
[8] Roch-Ramel F, Guisan B, Diezi J. Effects of uricosuric and antiuricosuric agents on urate transport in human brush-border membrane vesicles[J]. J Pharmacol Exp Ther,1997,280(2):839-845.
[9] Alderman MH, Cohen H, Madhavan S,et al. Serum uric acid and cardiovascular events in successfully treated hypertensive patients[J]. Hypertens,1999,34(1):144-150.
[10]Nindita Y,Hamada T,Bahrudin U. Effect of losartan and benzbromarone on the level of human urate transporter 1 mRNA[J]. Arzneimittelforschung,2010,60(4):186-188.
[11] Enomoto A, Niwa T, Kanai Y,et al.Urate transporter and renal hypouricemia[J]. Rinsho Byori,2003,51(9):892-897.
[12] Enomoto A, Kimura H, Chairoungdua A, et al.Molecular identification of a renal urate anion exchanger that regulates blood urate levels[J]. Nature,2002,417(6887):447-452.
[13] Jutabha P, Kanai Y, Hosoyamada M, et al.Identification of a novel voltage-driven organic anion transporter present at apical membrane of renal proximal tubule[J]. J Biol Chem,2003,278(30):27930-27938.
[14] Ichida K, Hosoyamada M, Hisatome I, et al.Clinical and molecular analysis of patients with renal hypouricemia in Japan-influence of URAT1 gene on urinary urate excretion[J]. J Am Soc Nephrol,2004, 15(1) :164-173.
[15] Vázquez-Mellado J, Jiménez-Vaca AL, Cuevas-Covarrubias S, et al. Molecular analysis of the SLC22A12 (URAT1) gene in patients with primary gout[J]. Rheumatology,2007,46(2):215-219.
[16] Tin A, Woodward OM, Kao WH, et al. Genome-wide association study for serum urate concentrations and gout among African Americans identifies genomic risk loci and a novel URAT1 loss-of-function allele[J]. Hum Mol Genet, 2011,20(20):4056-4068.
[17] Graessler J, Graessler A, Unger S, et al. Association of the human urate transporter 1 with reduced renal uric acid excretion and hyperuricemia in a German Caucasian population[J]. Arthritis Rheum, 2006,54(1):292-300.
[18] Li C, Han L, Levin AM, et al. Multiple single nucleotide polymorphisms in the human urate transporter 1 (hURAT1) gene are associated with hyperuricaemia in Han Chinese[J]. J Med Genet,2010,47(3):204-210.
[19] Shima Y, Teruya K, Ohta H. Association between intronic SNP in urate-anion exchanger gene, SLC22A12, and serum uric acid levels in Japanese[J]. Life Sci,2006,79(23):2234-2237.
[20] Graessler J,Graessler A,Unger S,et al.Association of the human Urate Transporter 1 with reduced renal uric acid excretion and hyperuricemia in a german caucasian population[J].Arthritis Rheum, 2006,54(1):292-300.
[21] Jang WC, Nam YH, Park SM, et al.T6092C polymorphism of SLC22A12 gene is associated with serum uric acid concentrations in Korean male subjects[J].Clinica Chimica Acta,2008,398(1/2):140-144.
[22] Hamada T, Ichida K, Hosoyamada M, et al. Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patients[J]. Am J Hypertens,2008,21(10):1157-1162.
[23] Zhu X, Chen J, Han F, et al. Efficacy and safety of losartan in treatment of hyperuricemia and posttransplantation erythrocytosis: results of a prospective, open, randomized, case-control study[J]. Transplant Proc,2009,41(9): 3736-3742.
[24] Nakashima M, Uematsu T, Kosuge K, et al. Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects[J]. Eur J Clin Pharmacol,1992,42(3):333-335.
[25] Sweet CS, Bradstreet DC, Berman RS,et al. Pharmacodynamic activity of intravenous E-3174, an angiotensin II antagonist, in patients with essential hypertension[J]. Am J Hypertens, 1994, 7(12):1035-1040.
[26] Cardona F, Tinahones FJ, Collantes E,et al.The elevated prevalence of apolipoprotein E2 in patients with gout is associated with reduced renal excretion of urates[J].Rheumatology (Oxford),2003,42(3):468-472.